Market revenue in 2022 | USD 1,218.9 millions |
Market revenue in 2030 | USD 2,370.1 millions |
Growth rate | 8.7% (CAGR from 2022 to 2030) |
Largest segment | Parasitic infections |
Fastest growing segment | Allergic Infections |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD millions |
Market segmentation | Parasitic Infections, Allergic Infections |
Key market players worldwide | Elanco Animal Health Inc, CEVA Inc, Vetoquinol SA, Merck & Co Inc, Zoetis Inc Class A, Virbac SA, Bimeda, Bioiberica, Boehringer Ingelheim Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to veterinary dermatology drugs market will help companies and investors design strategic landscapes.
Parasitic infections was the largest segment with a revenue share of 42.95% in 2022. Horizon Databook has segmented the Latin America veterinary dermatology drugs market based on parasitic infections, allergic infections covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America veterinary dermatology drugs market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America veterinary dermatology drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account